Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC25A | P30304 | 1/20 | 0.41 |
| ▸ | CDC25B | P30305 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | EEF2K | O00418 | 1/20 | 0.34 |
| ▸ | PLK1 | P53350 | 1/20 | 0.34 |
| ▸ | PLK2 | Q9NYY3 | 1/20 | 0.34 |
| ▸ | CES1 | P23141 | 3/20 | 0.33 |
| ▸ | CES2 | O00748 | 2/20 | 0.32 |
| ▸ | NSD2 | O96028 | 1/20 | 0.32 |
| ▸ | BCHE | P06276 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.30 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.30 |
| ▸ | DNMT3L | Q9UJW3 | 1/20 | 0.30 |
| ▸ | DNMT3A | Q9Y6K1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5590134 | 0.76 | CDC25A (0.42) | CDC25ACDC25BPTPN1EEF2KPLK1 | |
| SCHEMBL5590497 | 0.70 | CDC25A (0.41) | CDC25ACDC25BPTPN1EEF2KPLK1 | |
| SCHEMBL9655489 | 0.68 | EEF2K (0.47) | CDC25ACDC25BPTPN1EEF2KPLK1 | |
| SCHEMBL754972 | 0.66 | CDC25A (0.45) | CDC25ACDC25BPTPN1EEF2KPLK1 | |
| SCHEMBL17935505 | 0.66 | CDC25A (0.45) | CDC25ACDC25BPTPN1EEF2KPLK1 | |
| SCHEMBL5586949 | 0.65 | CDC25A (0.43) | CDC25ACDC25BPTPN1EEF2KPLK1 | |
| Water SCHEMBL28969836 | 0.64 | CDC25A (0.43) | CDC25ACDC25BPTPN1EEF2KPLK1 | |
| SCHEMBL13986038 | 0.62 | CDC25A (0.38) | CDC25ACDC25BPTPN1EEF2KPLK1 | |
| SCHEMBL6888742 | 0.62 | — | — | |
| SCHEMBL5588258 | 0.61 | CDC25A (0.41) | CDC25ACDC25BPTPN1EEF2KPLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7247687-B2 | Late transition metal catalysts for olefin polymerization and oligomerization | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2007-07-24 | — | — | US | disclosed |
| EP-1521758-B1 | LATE TRANSITION METAL CATALYSTS FOR OLEFIN POLYMERIZATION AND OLIGOMERIZATION | EXXONMOBIL CHEM PATENTS INC (US) | 2006-05-24 | — | — | EP | disclosed |
| US-20060047094-A1 | Late transition metal catalysts for olefin polymerization and oligomerization | EXXONMOBIL CHEMICAL PATENTS INC. | 2006-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060047094-A1 | Late transition metal catalysts for olefin polymerization and oligomerization | MLX, LOX, LMTK3 | CDC25A 1871/4885CDC25B 2427/4885PTPN1 4679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.